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Abstract 
Background: WHO recommends using Tenofovir containing first line antiretroviral therapy (ART), however, Tenofo-
vir has been reported to be associated with renal impairment and dysfunction. We compared renal function among 
individuals on Tenofovir and those on non-Tenofovir containing ART.
Methods: In a cross-sectional study of HIV-Positive adults on ART, at enrolment into a prospective cohort to study 
the long-term complications of ART in Uganda, information on biophysical measurements, medical history, clinical 
examination and renal function tests (RFTs) was collected. Fractional Tubular phosphate reabsorption and estimated 
glomerular filtration rate (eGFR) were calculated. Mean values of RFTs and proportions with abnormal RFTs were com-
pared between non-Tenofovir containing (Non-TDF) and Tenofovir containing (TDF-ART) ART regimen groups using a 
general linear regression model. Durations of TDF exposure were also compared.
Results: Between July 2013 and October 2014, we enrolled 953 individuals on ART for 6 or more months, median 
duration on ART was 9.3 years, 385 (40.4 %) were on non-TDF and 568 (59.6 %) on TDF-ART regimens. The proportion 
of participants with Proteinuria (>30 mg/dl) was higher among the TDF-ART group than the non-TDF ART group. 
However, in multivariable analysis, there were no significant differences in the adjusted mean differences of eGFR, 
serum urea, serum creatinine, fractional tubular reabsorption of phosphate and serum phosphates when patients on 
TDF-ART were compared with those on non-TDF containing ART. There were no differences in renal function even 
when different durations on Tenofovir were compared.
Conclusions: We found no differences in renal function among patients on Tenofovir and non-Tenofovir contain-
ing ART for almost a decade. Tenofovir based first line ART can therefore safely be initiated even in settings without 
routine renal function monitoring.
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Background
The WHO recommendation to use Tenofovir in first line 
antiretroviral therapy (ART) regimens has been widely 
adopted by ART programmes in Africa including Uganda 
[1–4]. Due to its cost, Tenofovir had been reserved for use 
with Protease inhibitors in second line ART regimens. 
Tenofovir is also used to treat hepatitis B virus infec-
tion, and its long intracellular half-life permits a once 
daily dosing, lower pill burden and facilitates adherence 
[5, 6]. However, Tenofovir is often associated with renal 
toxicity, manifesting as a decline in estimated glomeru-
lar filtration rate (eGFR), proximal renal tubular dysfunc-
tion and acute renal failure especially among patients 
with risk factors for kidney disease [7–14]. Variations in 
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the onset of Tenofovir associated renal impairment have 
been reported, in a randomised controlled trial, specific 
markers of proximal renal tubular function were derailed 
over 48 weeks in the Tenofovir group [15]. In a Canadian 
cohort, renal dysfunction was observed in the early years 
of exposure to Tenofovir but the risk remained minimal 
beyond 6 years [12]. The median time to develop Tenofo-
vir renal dysfunction was estimated at 154 (15–935) days 
in a clinical practice in western India [16]. Others have 
reported that tubular dysfunction or renal failure was 
diagnosed 6.89  ±  5.51  months after starting Tenofovir 
[17].
Studies of renal impairment among African patients on 
ART have reported differing prevalence. In S. Africa, the 
prevalence of severe (1.3 %) and moderate (13.1 %) renal 
impairment were reported [18], while in Western Kenya 
renal insufficiency was reported among 11.5 % of patients 
on ART [19]. In the DART Trial, there were no significant 
differences in the incidence of severe decline in eGFR 
between patients on Tenofovir containing and other ART 
regimens up to 4 years of therapy. However, patients who 
initiated Tenofovir based ART with a low eGFR had a 
greater risk of subsequent severe renal impairment [20]. 
A review on the renal safety of Tenofovir among HIV-
positive patients showed no evidence that Tenofovir 
use increased the risk of severe proteinuria, hypophos-
phatemia nor reduced eGFR [21]. However, most of these 
studies reported on short to mid-term Tenofovir associ-
ated renal toxicity, and not the renal dysfunction associ-
ated with the long-term use of Tenofovir.
The WHO “Treat all” immediate ART initiation strat-
egy for all HIV-Positive individuals and the use of Teno-
fovir based first line ART, will result in more HIV infected 
people getting exposed to Tenofovir [1, 2, 22]. Therefore, 
since ART is still a life-long intervention, information on 
the long-term changes in renal function among patients 
on Tenofovir containing ART is required to inform policy 
on how such patients should be monitored in the long-
term. In this study, we compared renal function among 
patients who were on or had ever been on Tenofovir with 
those on non-Tenofovir containing ART regimens.
Methods
Study design and settings
This cross-sectional study utilised data collected at 
enrolment into a prospective clinical cohort established 
in 2013 to study the Complications of long-term ART 
among HIV-Positive Ugandan adults (CoLTART). The 
study settings were the former Development of ART in 
Africa (DART) study clinic in Entebbe, Central Uganda 
[23], and the former Rural Clinical Cohort (RCC) study 
clinic in Kyamulibwa, South western Uganda [24].
Study population
Study participants were consenting HIV-Positive adults 
aged 18 years and above, on ART for 6 or more months 
recruited from two ART cohorts: (1) The DART Trial 
Cohort, which was established in 2003 as a multisite, ran-
domised clinical trial of monitoring strategy for the man-
agement of ART in adults with HIV infection in Africa 
[23]. After the DART Trial, study participants at the 
Entebbe site were followed up as a cohort. (2) The RCC 
which was established in 1990 to study the natural his-
tory of HIV infection in a rural Ugandan population [24], 
and free ART was introduced in 2004. Individuals who 
were too sick to undergo the study procedures, unable or 
unwilling to consent were excluded.
ART regimens
ART regimens were a standard two Nucleoside Reverse 
Transcriptase Inhibitor (NRTI) and one Non-NRTI first 
line ART regimen. An alternative first line ART regimen 
used in the DART Trial cohort was a triple nucleoside 
(3 NRTI). Second line ART was a combination of one 
or two NRTI and a ritonavir boosted Protease Inhibitor 
mainly Lopinavir.
Study procedures
Potential study participants received the study infor-
mation, underwent study eligibility assessment and 
consented for study participation. Data on socio-demo-
graphic, socio-economic status, behavioural and medical 
history of renal disease, hypertension and diabetes mel-
litus were collected and a clinical examination done. We 
measured body weight using the Seca digital measuring 
scale, height using a portable Seca 213 Leicester stadi-
ometer and blood pressure using the Omron M6 comfort 
automatic blood pressure monitor. Data on patients’ ART 
history was obtained from the electronic databases of the 
two former ART cohorts.
Specimen collection and laboratory methods
Venous blood was collected into three vaccutainer tubes, 
labelled and transported to the MRC Unit’s Clinical 
Diagnostic Laboratory Services for laboratory measure-
ments. Renal function tests (blood in a plain serum tube) 
and fasting blood glucose (blood in a Sodium fluoride 
tube) were measured using the Clinical chemistry ana-
lyser, Cobas Integra 400 plus (Roche Diagnostics). The 
blood in an EDTA tube was used for: (1) CD4 cell counts 
measurements using either the FACSCount or FACSCali-
bur machine (Becton–Dickinson, USA), and (2) Plasma 
HIV-1 RNA load measured using the COBAS Ampliprep/
Taqman V2.0 HIV-1 viral load assay (Roche Molecu-
lar Diagnostics (RMD), NJ, USA. All participants (apart 
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from women in their menses) provided a fresh mid-
stream urine specimen that was portioned in two plastic 
centrifuge tubes, one plain for urine creatinine and the 
other acidified for urine phosphates measurements; and 
both were measured using the Clinical chemistry ana-
lyser, Roche Integra 400 plus (Roche Diagnostics). Pro-
teinuria was measured using a Siemens Multistix 10SG 
urine dipstick strip test that was read using Clinitek Sta-
tus Analyzer (Siemens Healthcare Diagnostics).
Laboratory quality assurance
Standard operating procedures and internal quality 
measurements ensured internal quality control. The 
United Kingdom National External Quality Assurance 
Service (UKNEQAS), College of American Pathologists 
(CAP) and the Royal College of Pathologists of Australa-
sia (RCPA) were used for External quality Assurance for 
both haematological and biochemistry assays. Virology 
Quality Assurance Scheme (Rush University, Chicago, IL) 
was used for External quality Assurance for virological 
assays.
Statistical methods
Data were validated by double-entry on Ms Access sys-
tems and STATA 13 (Stata Corporation, College Sta-
tion, USA) was used for analyses. Renal function was 
determined using measured renal function tests, and 
calculated Fractional Tubular reabsorption of phosphate 
and estimated glomerular filtration rate (eGFR). Differ-
ent formulae were used to calculate eGFR; (a) the Cock-
croft-Gault formulae with and without body surface 
area (BSA) adjustment, (b) the Modified Diet in Renal 
Disease (MDRD) formulae with race adjustment (since 
all our participants were of the African race) and (c) the 
Chronic Kidney Disease Epidemiology (CKD-Epi) for-
mula. Abnormal measured renal function tests were 
defined as more than 11.9  mmol/L for serum urea, and 
more than 109 µmol/L for Serum creatinine. Serum phos-
phates (mmol/L) was categorised into; Hypophosphatae-
mia (<0.81), normal (0.81–1.5) and Hyperphosphataemia 
(>1.5), Proteinuria as >30 mg/dl of urine. Fractional Tubu-
lar phosphate reabsorption of less than 82  % and values 
of eGFR less than 60  ml/min/1.73  m2 were defined as 
abnormal. Diabetes mellitus was defined as a measured 
fasting blood glucose more than or equal to 6.4 mmol/l or 
history of being told by a professional health worker that 
one had diabetes mellitus or being on medication for dia-
betes mellitus prescribed by a professional health worker. 
Hypertension was defined as measured systolic blood 
pressure of more than or equal to 140 mmHg or diastolic 
blood pressure more than or equal to 90  mmHg or any 
history of being told by a professional health worker that 
one had raised blood pressure or hypertension or being 
on medication for raised blood pressure prescribed by a 
professional health worker.
Renal function outcomes were compared by Tenofovir 
exposure, as well as duration on Tenofovir and non-Ten-
ofovir containing ART regimens. Tenofovir exposure was 
categorised as participants on; (1) non-Tenofovir con-
taining ART regimen (Non-TDF), and (2) currently on or 
ever been on a Tenofovir containing ART regimen (TDF-
ART). For the two Tenofovir exposure groups, duration 
on ART was categorised into; less than 9 and 9 years or 
more.
Participants’ socio-demographic and economic char-
acteristics, lifestyle and anthropometric as well as clini-
cal, history of diseases and ART exposure were shown 
by Tenofovir exposure. Mean values of renal function 
outcomes and proportions with abnormal values were 
compared by Tenofovir exposure using general linear 
models and Chi-square tests, respectively. General linear 
regression models adjusted for age, sex, body mass index, 
duration on the current ART regimen, alcohol consump-
tion, viral load and CD4 cell counts were used to com-
pare mean values of renal function outcomes across the 
two Tenofovir exposure groups, as well as duration on 
Tenofovir and non-Tenofovir containing ART regimen. 
Adjusted mean differences in renal function outcomes, 
95  % confidence intervals for the mean differences, and 
significance levels are shown.
Results
Characteristics of study participants at enrolment
Between July 2013 and January 2014 we enrolled 953 
HIV-Positive individuals who had been on ART for 6 or 
more months, 628 (65.9 %) were females and 90.7 % were 
aged 35  years and above. The median duration on ART 
was 9.3  years and most participants (68.6  %) had been 
on ART for 9 or more years, 84.2 % had suppressed viral 
loads of less than 1000 copies/ml and 65.4 % had CD4 cell 
counts of 351 cells/µl or higher. The number of patients 
on non-Tenofovir containing ART (Non-TDF) was 385 
(40.4 %) while 568 (59.6 %) were or had been on a Teno-
fovir containing ART (TDF-ART) (Table 1).
Glomerular function
The overall proportions with renal dysfunction or renal 
failure and abnormal renal function assessment param-
eters were low among our study participants. How-
ever, in the unadjusted analysis, the mean eGFR was 
lower among the TDF-ART group than the non-TDF 
ART group using the CKD-Epi formula (P = 0.001) and 
MDRD formula with race adjustment (P = 0.008), but we 
found no differences in the mean eGFR calculated using 
the Cockcroft-Gault formulae (both with and without 
body surface area adjustment). Using all the four eGFR 
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formulae, although the proportions of participants with 
abnormal eGFR (<60  ml/min/1.73  m2) were higher 
among the TDF-ART than the non-TDF ART group, 
these differences were not significant. Overall, partici-
pants in the TDF ART group had higher mean serum 
urea levels (P  =  0.001) and higher mean serum creati-
nine levels (P = 0.023) than those in the non-TDF ART 
group, however the numbers with abnormal serum urea 
and creatinine levels were small (Table  2). In multivari-
able analysis, we found no significant differences in the 
adjusted mean differences in eGFR between TDF-ART 
and non-TDF ART groups using any of the formulae. We 
still found no significant differences in the adjusted mean 
differences of eGFR when different durations on different 
TDF exposure ART regimes were compared (Table 3). 
Renal tubular function
In the unadjusted analysis, the mean fractional tubu-
lar phosphate reabsorption was lower in the TDF-ART 
group than the Non-TDF ART group [mean (SD); 91.7 
(6.3) vs 92.7 (5.7), P  =  0.047]. However, we had few 
patients with abnormal fractional tubular phosphate 
reabsorption mean values and no significant differ-
ences were found between the two comparison groups. 
The proportion of patients with proteinuria (30  mg/dl 
or more) was higher in the TDF-ART group [n =  121 
(22.0  %)] than in the Non-TDF ART group [n  =  43 
(11.3  %)], P  <  0.001. The mean serum phosphates was 
Table 1 Characteristics of  participants who had been 
on ART for more than 6 months at enrolment by Tenofovir 
Disoproxil Fumarate (TDF) exposure
Characteristics All  
participants
n (%)
TDF exposure
Non-TDF ART
n (%)
TDF ART
n (%)
Alla 953 385 (40.4) 568 (59.6)
Socio-demographic/economic
Age (years)
 18–34 89 (9.3) 45 (11.7) 44 (7.7)
 35–49 578 (60.7) 222 (57.7) 356 (62.7)
 50+ 286 (30.0) 118 (30.6) 168 (29.6)
Sex
 Females 628 (65.9) 250 (64.9) 378 (66.5)
 Males 325 (34.1) 135 (35.1) 190 (33.5)
SES score tertileb
 Low 403 (42.3) 165 (42.9) 238 (41.9)
 Middle 359 (37.7) 144 (37.4) 215 (37.9)
 High 186 (19.5) 76 (19.7) 110 (19.4)
Lifestyle, anthropometric
Tobacco consumption
 Never 791 (83.0) 305 (79.2) 486 (85.6)
 Ex-smoker 93 (9.8) 39 (10.1) 54 (9.5)
 Current 68 (7.1) 41 (10.6) 27 (4.8)
Alcohol consumption
 Never 358 (37.6) 141 (36.6) 217 (38.2)
 Ever >1 month 352 (36.9) 135 (35.1) 217 (38.2)
Within <1 month 234 (24.6) 108 (28.1) 126 (22.2)
Body Mass Index (kg/m2)
 <18.5 91 (9.5) 30 (7.8) 61 (10.7)
 18.5–24.9 591 (62.0) 263 (68.3) 328 (57.7)
 25.0-29.9 192 (20.1) 69 (17.9) 123 (21.7)
 ≥30 60 (6.3) 18 (4.7) 42 (7.4)
Clinical, disease history, art
Hypertension
 Normal 722 (75.8) 299 (77.7) 423 (74.5)
 Hypertensive 220 (23.1) 83 (21.6) 137 (24.1)
Glucose (mmol/lL)/history
 Desirable (≤6.4 mmol/l) 912 (95.7) 375 (97.4) 537 (94.5)
 High (>6.4 mmol/l) 33 (3.5) 10 (2.6) 23 (4.0)
Renal disease history
 No renal disease 946 (99.3) 383 (99.5) 563 (99.1)
 Known renal disease 6 (0.6) 2 (0.5) 4 (0.7)
ART regimen type/class
 First line ART
 2NRTIs/NNRTI 481 (50.5) 312 (81.0) 169 (29.8)
 3NRTIs 237 (24.9) 41 (10.6) 196 (34.5)
 Second line ART (with 
boosted PI)
235 (24.7) 32 (8.3) 203 (35.7)
Cotrimoxazole use
 Yes 570 (59.8) 161 (41.8) 409 (72.0)
a Percentages in brackets show percentage of TDF or non-TDF containing ART 
over all patients on ART
b SES is socio-economic status index calculated over the total items owned. 
Hypertension defined as SBP ≥140 mmHg or DBP ≥90 or any history of 
hypertension
Table 1 continued
Characteristics All  
participants
n (%)
TDF exposure
Non-TDF ART
n (%)
TDF ART
n (%)
 No 383 (40.2) 224 (58.2) 159 (28.0)
Total duration on ART (years)
 0.5 to <5 175 (18.4) 138 (35.8) 37 (6.5)
 5 to <9 124 (13.0) 79 (20.5) 45 (7.9)
 9+ 654 (68.6) 168 (43.6) 486 (85.6)
HIV-1 viral load (copies/ml)
 <1000 802 (84.2) 346 (89.9) 456 (80.3)
 1000–9999 48 (5.0) 13 (3.4) 35 (6.2)
 10,000+ 71 (7.5) 15 (3.9) 56 (9.9)
CD4 cell counts (cells/µl)
 ≤350 263 (27.6) 102 (26.5) 161 (28.3)
 351–500 274 (28.8) 120 (31.2) 154 (27.1)
 501+ 349 (36.6) 149 (38.7) 200 (35.2)
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slightly higher in the TDF-ART group (1.1 mmol/L, SD 
0.3), than in the Non-TDF ART group (1.0  mmol/L, 
SD 0.2), P  =  0.023, but the proportions of patients 
with hypophosphataemia were higher among the Non-
TDF ART [n = 64 (16.6 %)] than the TDF-ART group 
[n  =  58 (10.6  %)], P  =  0.012 (Table  2). In multivari-
able analysis, when the TDF-ART and Non-TDF ART 
groups were compared, we found no significant dif-
ferences in the adjusted mean differences in the frac-
tional tubular reabsorption of phosphate and serum 
phosphates. We still found no significant differences 
in the adjusted mean differences of fractional tubular 
reabsorption of phosphate and serum phosphates when 
durations on  the two TDF exposure ART groups were 
compared (Table 3).
Discussion
In this cross-sectional study among HIV-Positive individ-
uals on antiretroviral therapy for a median of 9.3  years, 
we found no differences in renal function (eGFR and 
fractional tubular phosphate reabsorption) among 
patients on Tenofovir and Non-Tenofovir containing 
Table 2 Renal dysfunction or failure and mean values of renal function assessment parameters among patients with and 
without Tenofovir Disoproxil Fumarate containing ART regimen
BSA adj body surface area adjustment
* P value showing evidence for mean differences in estimated parameters by TDF exposure (in italics) and Chi-square test P value (not in italics). Renal dysfunction/
failure defined as eGFR: <60 ml/min/1.73 m2. Some missing eGFR values due to missing some anthropometric measures used to calculate eGFR e.g. patients who 
could not stand upright because of being lame
Renal function assessment parameter All participants
n (%)
TDF exposure P value*
Non-TDF ART n (%) TDF ART n (%)
All 953 385 (40.4) 568 (59.6)
eGFR (Cockcroft-Gault, adj for BSA), mean (SD) 108.6 (37.0) 110.0 (36.0) 107.3 (36.8) 0.197
 Normal 901 (97.0) 371 (97.6) 530 (96.5) 0.338
 Renal dysfunction/failure 28 (3.0) 9 (2.4) 19 (3.5)
eGFR (Cockcroft-Gault, without BSA adj), mean (SD) 104.9 (68.4) 103.6 (58.9) 104.6 (71.3) 0.933
 Normal 874 (93.9) 363 (95.3) 511 (92.9) 0.139
 Renal dysfunction/failure 57 (6.1) 18 (4.7) 39 (7.1)
eGFR (CKD-Epi), mean (SD) 102.9 (18.0) 105.3 (17.5) 101.7 (18.2) 0.001
 Normal 929 (98.1) 378 (98.2) 551 (98.0) 0.878
 Renal dysfunction/failure 18 (1.9) 7 (1.8) 11 (2.0)
eGFR (MDRD with race), mean(SD) 131.7 (43.8) 135.9 (47.0) 128.9 (40.2) 0.008
 Normal 935 (98.7) 382 (99.2) 553 (98.4) 0.267
 Renal dysfunction/failure 12 (1.3) 3 (0.8) 9 (1.6)
Fractional Tubular PO4 reabsorption %, mean (SD) 92.1 (6.1) 92.7 (5.7) 91.7 (6.3) 0.047
 Normal 734 (95.7) 325 (95.3) 409 (96.0) 0.634
 Abnormal Fractional Tubular PO4 reabsorption 33 (4.3) 16 (4.7) 17 (4.0)
Proteinuria on dipstick (mg/dl)
 Negative 646 (69.5) 298 (78.6) 348 (63.2) <0.001
 Trace (1–30) 120 (12.9) 38 (10.0) 82 (14.9)
 Positive (30+) 164 (17.6) 43 (11.3) 121 (22.0)
Serum urea (mmol/L), mean (SD) 3.1 (1.3) 3.0 (1.2) 3.2 (1.4) 0.001
 Desirable 944 (99.8) 384 (100.0) 560 (99.6) 0.242
 Abnormal (>11.9) 2 (0.2) 0 (0.0) 2 (0.4)
Serum creatinine (µmol/L), mean (SD) 65.5 (20.3) 64.0 (18.5) 66.8 (20.8) 0.023
 Desirable 930 (98.2) 381 (99.0) 549 (97.7) 0.147
 Abnormal (>109) 17 (1.8) 4 (1.0) 13 (2.3)
Serum phosphates (mmol/L), mean (SD) 1.0 (0.3) 1.0 (0.2) 1.1 (0.3) 0.023
 Hypophosphataemia (<0.81) 122 (13.1) 64 (16.6) 58 (10.6) 0.012
 Normal (0.81–1.5) 799 (85.5) 318 (82.6) 481 (87.6)
 Hyperphosphataemia (>1.5) 13 (1.4) 3 (0.8) 10 (1.8)
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ART regimens. Even with different durations on ART, 
we still found no significant differences in renal function 
among patients by TDF exposure ART group. These find-
ings might allay concerns raised about the renal toxicity 
of Tenofovir which is recommended for initiating ART 
by the WHO, and has been widely adopted by ART pro-
grammes in many resource limited countries including 
Uganda [1–4].
Previous studies have documented the association 
between Tenofovir and renal dysfunction, leading to glo-
merular and proximal renal tubular damage and acute 
renal failure [8–14]. However, we found no differences 
in glomerular function between patients who were on 
Tenofovir containing ART and those who were on Non-
Tenofovir containing ART. Other studies have similarly 
reported no or minimal reductions in glomerular filtra-
tion rate among patients on Tenofovir [17, 21, 25]. Simi-
larly, a 10  year follow-up cohort study of HIV-positive 
patients, reported that the quantified loss in eGFR attrib-
utable to Tenofovir was relatively modest after many 
years of exposure [12]. Since the majority of our patients 
had been on ART for more than 9  years, our failure to 
find an association between renal dysfunction and dura-
tion on Tenofovir containing ART can be explained 
by previous studies that reported that the loss in eGFR 
attributable to Tenofovir seemed to occur during the first 
years of exposure between 0.5 and 31.2 months and sta-
bilized after that [16, 17, 25–28]. Post marketing studies 
reported advanced age, low body weight, comorbidities 
such as diabetes  mellitus, hypertension, as some of the 
risk factors for Tenofovir induced renal dysfunction [27, 
29, 30]. Therefore, our finding of no differences in renal 
function between the Tenofovir and non-Tenofovir con-
taining ART regimens might be explained by the small 
proportions of individuals aged above 50  years, low 
BMI  <  18.5  kg/m2, with high blood sugar, hypertension 
and known renal disease. One study reported that the 
odds of developing significant renal dysfunction was 3.7 
times higher among patients receiving Tenofovir and 
ritonavir-boosted Protease inhibitor (boosted-PI) regi-
mens than those receiving Tenofovir and non-nucleoside 
reverse transcriptase inhibitor-based therapy [30]. This 
might explain our finding of no increase in renal dysfunc-
tion among patients on Tenofovir, as in our study, only 
24.7 % on were on second line ART containing Tenofovir 
and a boosted PI.
We observed a higher proportion of patients with 
proteinuria (>30  mg/dl) among patients on Tenofovir 
containing ART than those on Non-Tenofovir ART regi-
mens. The significant presence of proteinuria among the 
TDF-ART group when compared to the Non-TDF ART 
group can be explained by the fact that proteinuria is a 
presentation of subclinical proximal tubular dysfunc-
tion without glomerular function impairment [11, 31]. 
Our findings are comparable to reports from a retrospec-
tive cohort of HIV infected US veterans where Tenofovir 
Table 3 Adjusted mean differences in  renal function assessment parameters among  patients on TDF and  without TDF 
containing ART
BUN blood urea nitrogen, BSA adj body surface area adjustment, race adj race adjustment
* P value showing evidence for adjusted mean differences in renal function parameters by ART regimen type, and duration
a aMD (95 % CI) is adjusted mean difference with 95 % Confidence Interval, adjusted for site, duration on ART for those on non-TDF and duration on TDF among those 
on TDF, tobacco consumption, socio-economic status index, viral load, CD4 cell counts, hypertension and history of diabetes mellitus or high glucose levels
Renal function assess-
ment parameter
Tenofovir (TDF) ART exposure duration on TDF or non-TDF containing ART
TDF versus non-TDF P value* Non-TDF 9 + y ver-
sus non-TDF < 9y
TDF < 9y versus non-
TDF < 9y
TDF 9 + y versus non-
TDF < 9y
P value*
aMD (95 % CI)a aMD (95 % CI)a aMD (95 % CI)a aMD (95 % CI)a
eGFR (Cockcroft-Gault, 
with BSA adj)
−2.26 (−8.46 to 3.94) 0.472 −2.97 (−13.97 to 8.03) 3.79 (−6.68 to 14.26) −7.39 (−18.10 to 3.32) 0.200
eGFR (Cockcroft-Gault, 
without BSA adj)
−2.79 (−14.50 to 8.93) 0.638 −4.40 (−25.21 to 16.42) 1.30 (−18.50 to 21.11) −8.43 (−28.70 to 11.84) 0.778
eGFR (CKD-Epi) −0.97 (−3.85 to 1.91) 0.507 −0.32 (−5.44 to 4.79) 2.92 (−1.95 to 7.80) −2.83 (−7.82 to 2.16) 0.114
eGFR (MDRD with race 
adj)
−0.30 (−7.58 to 6.98) 0.935 −2.68 (−15.61 to 10.25) 7.26 (−5.05 to 19.57) −5.77 (−18.37 to 6.83) 0.248
Fractional tubular PO4 
reabsorption, % (SD)
−0.47 (−1.54 to 0.61) 0.390 −0.16 (−2.01 to 1.68) −0.86 (−2.63 to 0.91) −0.44 (−2.24 to 1.36) 0.786
Urea BUN 0.07 (−0.14 to 0.29) 0.503 −0.05 (−0.43 to 0.33) 0.28 (−0.08 to 0.65) −0.05 (−0.43 to 0.32) 0.302
Serum creatinine 
(µmol/L)
2.47 (−0.86 to 5.81) 0.143 −2.51 (−8.44 to 3.42) −1.53 (−7.17 to 4.12) 1.81 (−3.97 to 7.59) 0.161
Serum phosphates 
(mmol/L)
0.00 (−0.04 to 0.05) 0.913 −0.01 (−0.09 to 0.08) 0.03 (−0.05 to 0.11) −0.01 (−0.09 to 0.07) 0.823
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use was found to be associated with an increased risk of 
proteinuria and chronic kidney disease [32]. Although in 
univariate analysis we observed a lower mean fractional 
tubular phosphate reabsorption among patients on TDF-
ART than those on Non-TDF ART, the differences were of 
borderline significance and disappeared in multivariable 
analysis. We found that the proportion of patients with 
hypophosphataemia was higher among patients on Non-
TDF ART than those on TDF-ART regimens. However, 
a study that assessed renal tubular dysfunction during 
long-term Adefovir or Tenofovir therapy in chronic Hepa-
titis B infection reported that 7 (14 %) out of 51 patients 
developed persistent hypophosphataemia, with urinary 
phosphate wasting and a low (<82 %) estimated fractional 
tubular reabsorption of phosphate, but their sample size 
was small and they lacked a comparison group [33].
Our study strengths included the availability of a com-
parison group of patients on non-Tenofovir containing 
ART which enabled control for residual confounding. 
We also assessed glomerular function as well as proximal 
renal tubular function since Tenofovir has been reported 
to affect both renal functions. The long duration of our 
patients on ART, allowed us to document the effect of 
long-term Tenofovir exposure. Most previous reports 
were of shorter duration on Tenofovir, because in sub 
Saharan Africa, due to its cost, Tenofovir was previously 
reserved for second line ART.
We acknowledge some limitations that might have 
affected our study findings; a small number of patients 
(50) had discontinued Tenofovir but we did not consider 
the period since Tenofovir was discontinued and the rea-
sons why it was discontinued. If Tenofovir was stopped 
due to Tenofovir induced renal dysfunction, this might 
have biased our results especially if the duration since 
Tenofovir stoppage was short. Although none of our par-
ticipants was known to be using nephrotoxic medications 
like amphotericin, and we did not collect data on previ-
ous use of such medications, some residual confound-
ing is still possible. Since samples collected for HBV and 
HCV testing have not yet been tested, we did not assess 
the effect of these co-infections on renal function among 
our study participants. Due to the cross-sectional study 
design of our study, assessing single point proteinuria 
instead of the more clinically significant persistent pro-
teinuria might have biased our findings. We could not 
compare our findings with the pre-ART renal function 
because in our setting, routine renal function test meas-
urements are not done prior to ART initiation. Further-
more, because our patients were former research study 
participants with close monitoring, our findings may 
not be generalizable to the general population of HIV-
infected patients who receive ART in the general HIV 
care programmes.
Conclusions
In conclusion, we found no differences in eGFR and frac-
tional tubular phosphate reabsorption among patients 
on Tenofovir and non-Tenofovir containing ART after 
a median of 9.3  years on ART. Since in most resource 
limited settings, routine renal function testing prior to 
ART initiation and monitoring during treatment is not 
always feasible, our results are reassuring as ART pro-
grammes adopt the WHO recommendation to use Ten-
ofovir in first line ART regimens. Therefore, the WHO 
recommended Tenofovir based first line ART can safely 
be initiated even in settings without routine renal func-
tion monitoring. However, the higher proteinuria among 
patients on Tenofovir containing ART in the absence of 
a corresponding higher impairment of fractional tubular 
phosphate reabsorption suggests a subclinical proximal 
tubular dysfunction, therefore targeted renal function 
monitoring for specific patients should be undertaken 
when clinically indicated. Further evaluation of renal 
function among patients on Tenofovir beyond 10 years is 
advised.
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